LY3437943 (Retatrutide): discovery to clinical proof of concept (triple GLP-1/GIP/glucagon agonist, preclinical mechanism) Nature Reviews Endocrinology (2024) Multi-receptor agonists for metabolic disease (mechanism of GLP-1/GIP/glucagon co-activation) Diabetes Care (2024) Incretin-based therapies: GLP-1, GIP, and glucagon receptor pharmacology (metabolic pathways, energy expenditure) NEJM (2023) Supplementary Material Jastreboff et al
Those with a history of cancer Since growth hormone-related peptides can influence cell signaling, individuals with a history of tumors should exercise caution
Plan: Continue iron
Common Subcutaneous Injection Sites Lower abdomen, avoiding the area two inches around the navel Upper outer thighs Upper glutes Upper outer arms Certain peptides, such as BPC-157 or TB-4, may be injected closer to an injury site if advised by your provider
Step 1: Wash Hands and Prepare the Workspace Wash hands thoroughly with soap and water for at least 20 seconds
Step 7: Swirl Gently Until Dissolved Remove the syringe
